Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

被引:265
作者
Brendel, Karl [1 ]
Comets, Emmanuelle
Laffont, Celine
Laveille, Christian
Mentre, France
机构
[1] INSERM, U738, Paris, France
[2] Univ Paris 07, Paris, France
[3] Hop Bichat, AP HP, F-75877 Paris, France
[4] Inst Rech Int Servier, F-92415 Courbevoie, France
[5] Exprimo NV, Lummen, Belgium
关键词
external validation; metrics; model evaluation; population pharmacokinetics; posterior predictive check;
D O I
10.1007/s11095-006-9067-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The aim of this study is to define and illustrate metrics for the external evaluation of a population model. Materials and Methods. In this paper, several types of metrics are defined: based on observations (standardized prediction error with or without simulation and normalized prediction distribution error); based on hyperparameters (with or without simulation); based on the likelihood of the model. All the metrics described above are applied to evaluate a model built from two phase II studies of gliclazide. A real phase I dataset and two datasets simulated with the real dataset design are used as external validation datasets to show and compare how metrics are able to detect and explain potential adequacies or inadequacies of the model. Results. Normalized prediction errors calculated without any approximation, and metrics based on hyperparameters or on objective function have good theoretical properties to be used for external model evaluation and showed satisfactory behaviour in the simulation study. Conclusions. For external model evaluation, prediction distribution errors are recommended when the aim is to use the model to simulate data. Metrics through hyperparameters should be preferred when the aim is to compare two populations and metrics based on the objective function are useful during the model building process.
引用
收藏
页码:2036 / 2049
页数:14
相关论文
共 34 条
  • [1] Role of modelling and simulation in Phase I drug development
    Aarons, L
    Karlsson, MO
    Mentré, F
    Rombout, F
    Steimer, JL
    van Peer, A
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) : 115 - 122
  • [2] POPULATION PHARMACOKINETICS OF TOBRAMYCIN
    AARONS, L
    VOZEH, S
    WENK, M
    WEISS, P
    FOLLATH, F
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (03) : 305 - 314
  • [3] BAYARRI MJ, 2000, JASA, V95, P1143
  • [4] Ways to fit a PK model with some data below the quantification limit
    Beal, SL
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) : 481 - 504
  • [5] Beal SL., 1989, NONMEM 7 4 USERS GUI
  • [6] Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in western and Japanese patients
    Comets, E
    Ikeda, K
    Hoff, P
    Fumoleau, P
    Wanders, J
    Tanigawara, Y
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2003, 30 (04) : 257 - 283
  • [7] Comets E, 2001, J Biopharm Stat, V11, P107, DOI 10.1081/BIP-100107652
  • [8] A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: The antiemetic effect of ondansetron
    Cox, EH
    Veyrat-Follet, C
    Beal, SL
    Fuseau, E
    Kenkare, S
    Sheiner, LB
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1999, 27 (06): : 625 - 644
  • [9] Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers
    Delrat, P
    Paraire, M
    Jochemsen, R
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2002, 23 (04) : 151 - 157
  • [10] Stability and performance of a population pharmacokinetic model
    Ette, EI
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (06) : 486 - 495